Trial Profile
A Phase 1 Proof of Concept Study Evaluating Intravitreal AAVCAGsCD59 for the Treatment of Wet Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs HMR-59 (Primary) ; Aflibercept; Bevacizumab; Prednisolone; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 24 May 2022 Status changed from active, no longer recruiting to completed.
- 03 Sep 2020 Planned End Date changed from 6 Feb 2021 to 29 Jan 2022.
- 29 Jan 2020 Status changed from recruiting to active, no longer recruiting.